Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39bf0bb8b07e151d4bcead749d7dd699 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16071 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
filingDate |
2021-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2022-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-4032546-A1 |
titleOfInvention |
Therapeutic viral vaccine |
abstract |
The present invention relates to a nucleic acid encoding a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a nucleic acid encoding a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject. |
priorityDate |
2021-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |